Lymphoma Treatment Shifted to Outpatient Care
New evidence shows patients with large B-cell lymphoma can safely receive epcoritamab in outpatient settings.
Updated on Sept. 29, 2026 in Cancer
The EPCORE NHL-1 trial demonstrated that subcutaneous epcoritamab effectively treats patients with relapsed or refractory large B-cell lymphoma. Findings published on September 29, 2026, suggest this regimen can now be managed with outpatient protocols.
Why it matters
Transitioning from routine hospitalization to outpatient monitoring for side effects improves access and quality of life for patients undergoing this cancer therapy. This approach leverages systematic risk management to handle potential reactions outside of a clinical ward.
The EPCORE NHL-1 clinical trial evaluated subcutaneous epcoritamab in patients with relapsed or refractory large B-cell lymphoma, including those with prior CAR T-cell therapy. The results confirmed complete response rates, establishing a foundation for outpatient care delivery.
The players
EPCORE NHL-1
A clinical trial evaluating the safety and efficacy of subcutaneous epcoritamab in patients with relapsed or refractory B-cell lymphoma.
The details
Epcoritamab is administered through a step-up dosing schedule that now utilizes remote monitoring and at-home steroid plans. To manage cytokine release syndrome, physicians employ dexamethasone or prednisone prophylaxis alongside structured hydration. By shifting from routine hospitalization to risk-based admission for the initial full dose, medical teams can minimize unnecessary inpatient stays while monitoring for infrequent neurotoxicity.
Timeline
September 29, 2026: Findings from the EPCORE NHL-1 trial were published.
Health Landscape
The treatment of large B-cell lymphoma is evolving from intensive inpatient requirements to more flexible, outpatient-centered delivery models. The EPCORE NHL-1 trial underscores this shift, marking a transition toward integrating complex biologics into standard ambulatory care.
Patients and their families should discuss the feasibility of outpatient management and remote monitoring with their oncology team. It is essential to ensure that a robust support plan, including steroid prophylaxis and rapid access to care, is in place before initiating treatment.
The takeaway
The successful implementation of outpatient epcoritamab therapy represents a significant logistical improvement in lymphoma care. Patients should consult with their hematologist to understand the specific safety protocols and monitoring requirements for their care plan.
Further reading
Learn more about the latest innovations in Cancer treatment and research.
